NVAX trade ideas
$NVAX Play The Break Out Above $18$NVAX is setting up as nice day trade if we get above $18 and the 52 week high of $18.25 a share. We could see $20 a share pretty easy, especially with the news out today.
MELBOURNE, Australia, April 16, 2020 /PRNewswire/ -- As part of the urgent global race to develop a vaccine to tackle the Coronavirus COVID-19 outbreak, Nucleus is due to commence Phase 1 testing for the Novavax SARS-CoV-2 Recombinant Spike Protein Nanoparticle vaccine, NVX-CoV2373, at its Melbourne and Brisbane clinics within the coming weeks.
"Nucleus has a rich history of Phase 1 vaccine trials, and a long-standing track-record with Novavax (NVAX)," says Nucleus CEO Cameron Johnson. "This is the third confirmed global COVID19 vaccine trial and the first in Australia and we are well positioned to implement rapid testing with first-in-human trials over the coming weeks.
"With the capacity to conduct this trial across both our Melbourne and Brisbane clinics, we will be assisting Novavax to undertake Phase 1 trials and fast track NVX-CoV2373 to potential subsequent development as soon as possible," adds Johnson.
Novavax's early development efforts on vaccines for two other recent coronavirus epidemics – severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), along with prior work on Ebola (phase 1 trial conducted in Australia) – allows them to leverage their understanding of coronaviruses and adapt their research to create a vaccine for SARS-CoV-2, the virus that causes COVID-19.
"The urgent global race to develop a vaccine against the COVID-19 pandemic drove our rapid identification and selection of an optimal, highly immunogenic vaccine candidate," said Stanley C. Erck, President and CEO of Novavax. "We are pleased that Nucleus, our long-time partner, was able to accommodate our accelerated timeline."
The Phase 1 trial of NVX-CoV2373 is expected to begin in mid-May with preliminary immunogenicity and safety results in July.
The scale and absolute commitment to the highest standards make Nucleus the ideal partner in the rapid development of the vaccine for COVID-19.
"We own 150 of the total 250 dedicated phase I beds available in Australia over two sites in Melbourne and Brisbane, located within major medical precincts. Supported by our workforce of over 400 specialists, we are in the unique position of offering sponsors a multi-site pathway to conduct their clinical trials," says Johnson.
This scale allows Nucleus to address the urgency of the COVID-19 vaccine studies, without interruption to other ongoing clinical trials. The standards ensure the reliability of the studies, especially in the current pandemic situation across the world.
"For all of our clinical trials, Nucleus has implemented the highest level of Transmission-Based Precautions within its clinical units including the creation of dedicated teams of clinical staff," says Nucleus Infectious Diseases Physician and Microbiologist and, Associate Professor of Medicine at the University of Queensland, Dr Paul Griffin. "These staff are assigned to work only in functional designated areas and there is no cross-pollination of these teams, improving safety, reducing study risk, and ensuring integrity of the trials."
As a key partner in the development of these promising vaccine candidates, Nucleus' role in solving the current pandemic is top of mind for Johnson.
"As COVID-19 continues to impact the everyday life of all global citizens, finding a solution has become an urgent objective for governments and health organisations around the world. The world is watching and we're on the front line, supporting Novavax to unlock the potential of a Coronavirus COVID-19 vaccine."
Good luck to all!
It's hard to overstate how important the NVAX Phase 3 result isNovavax's Nanoflu isn't your typical new drug-- it's a whole new pharmaceutical technology. So it's hard to overstate how important today's positive Phase 3 clinical trial result is.
Positive Phase 3 trial data this morning suggest that Novavax's Virus-Like Particle (VLP)-based flu vaccines will be much more effective than existing egg-based vaccines. When you make a vaccine in an egg, it can mutate in the egg and no longer match the flu strains it's supposed to prevent. The VLP vaccines, by contrast, are genetically identical to the targeted flu strains. This increases the vaccines' effectiveness against the targeted strains.
Nanoflu also includes something called "adjuvant Matrix-M," which increases the number of antibodies produced in response to the vaccine by something on the order of 50%. Stronger immune response means greater effectiveness, though it also modestly increased the incidence of adverse events in Novavax's trial. One particular important result from the Phase 3 trial was that Nanoflu was more effective than its competitors against A/H3N2, the most lethal family of flu viruses and the one against which vaccines have traditionally been least effective.
I have some friends doing work in this field, and they've told me that there are three really exciting things about these VLP vaccines: 1) they aren't infectious, which makes them safer than using an attenuated virus, 2) they protect against not only the strain of virus they target, but also some mutant forms of it, and 3) they take 12 weeks to produce rather than the traditional 9 months. This last point is the real game-changer. Imagine being able to get vaccines to market in a third of the traditional time.
Novavax is also working on a VLP-based Covid-19 vaccine. We can probably expect the FDA to rush approval of both Nanoflu and the CoV-19 vaccine.
Double top Wedge OverextensionI can feel the dump. We've formed a double top with this second leg creating a wedge as well as an over-extension of the Tenkan-sen. If not ripe for a reversal certainly a pullback--at least that's what I'm betting on.
Novavax $NVAX#Novavax hit the weekly 100SMA and stalling and forming double top. It may pull back on next week.
$NVAX long swing ideaReally sweet cup with handle set-up here in $NVAX. I'm long 200 @ $14.30 with $13.30 stop loss. Looking for a move back up to the recent highs near $17.70ish
$NVAX Novavax identifies COVID-19 VAccine Novavax, Inc. (NASDAQ: NVAX) today announced it has identified a coronavirus vaccine candidate, NVX-CoV2373, a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology, and will initiate a first-in-human trial in mid-May. Novavax’ proprietary Matrix-M™ adjuvant will be incorporated with NVX-CoV2373 in order to enhance immune responses and stimulate high levels of neutralizing antibodies.
NVX-CoV2373 was shown to be highly immunogenic in animal models measuring spike protein-specific antibodies, antibodies that block the binding of the spike protein to the receptor and wild-type virus neutralizing antibodies. High levels of spike protein-specific antibodies with ACE-2 human receptor binding domain blocking activity and SARS-CoV-2 wild-type virus neutralizing antibodies were observed after a single immunization. In addition, the already high microneutralization titers seen after one dose increased eight fold with a second dose. High titer microneutralizing antibodies are generally accepted evidence that a vaccine is likely to be protective in humans.
Source street insider
$NVAX Possible Gap FillMy only issue with the price action are these two candles highlighted in green. The April 3rd close of 15.61 is within the midranges of the real bodies both of which are positioned at two highest peaks of resistance during the buildup of this base in the 4.00 area. A fill to the upside will be very nice with this chart.
NVAX -- reaching a resistance top of channelNVAX -- reaching a resistance top of channel --- lets see if turns back down temprarily... PLUS its FRIDAY end of DAY. I DO NOT HOLD over the weekend ---- regardless of outcomes. THIS IS A 2 hour channel im talking about --- there is still room up to $18 at NEXT resistance point -- if continues upwards before the NEXT resistance point in charting the daily's (VERY VOLITILE REGARDLESS) so basically dont hold your breathe. QUICK TRADES AND GO BACK TO CASH is my method.
Be safe.
Just my opinions here.
Thank you.
___________________________________
Disclaimer:
Always do your own due diligence, full research, and homework, and consult with your own licensed investment professional before any investments. Any comments and analysis seen here are personal opinions, and we are not registered or licensed in any jurisdiction whatsoever to provide any investing advice. Any analysis, charting and comments should never be used for the purposes of assisting in any advisory decisions with any stock purchase or sale, and never to be used on the basis of making any kind of investment decisions. It is for the sole purposes of opinions and thoughts only of the markets. Thank you.
NVAX Cup and HandleNVAX is showing some strength to push upward toward the $14 level. At that point it could break out reaching back to the $16 level. A cup and handle rounding formation is happening. Looking for the handle breakout.
NVAX RetestNVAX restested its breakout level of $10 and held. I was lucky enough to get in at the $10.5 range before it continued further upside. Looking for a quick target of $14 due to its volatility before earnings.
$NVAX Dances While the Music Plays, But What's Next?NVAX ramped on the squeeze as crowd psychology and algorithmic logic took hold in the market crash last week. But this company has as much chance of participating in the actual vaccine as my aunt's family chicken soup recipe. We look for the fade.
NVAX - closing gaps! - fast down as mentioned... earlyNVAX - closing gaps! - fast down as mentioned... early. DROP HARD. as was mentioned it would do. early monring. (Now lets see where it goes from here after 10am.)
___________________________________
Disclaimer:
Always do your own due diligence, full research, and homework, and consult with your own licensed investment professional before any investments. Any comments and analysis seen here are personal opinions, and we are not registered or licensed in any jurisdiction whatsoever to provide any investing advice. Any analysis, charting and comments should never be used for the purposes of assisting in any advisory decisions with any stock purchase or sale, and never to be used on the basis of making any kind of investment decisions. It is for the sole purposes of opinions and thoughts only of the markets. Thank you.
Pharma Stocks Don't move MuchWell for some reason the News is Killing the Market, I am down 60% Today, so decided to look at things with a different Light. Which ones Move differently depending on the Hype / News that is in our Ears.
Got this one for $10 and next day it was $16 that might be the top for this one but Maybe not? I did not draw on the Chart but you can see it took off like a Rocket. There are Three Stocks that are dealing directly with Coronavirus this one was moderate price so I went with this guy. If it gets close to some of their previous levels could be interesting month. Just thought I would share.
Have a good day and don't forget to Wash your Hands.
Novavax (NVAX) - Vaccine Testing - SARS, MERS, SARS-CoV-2 (2019)This is an interesting idea based on outbreaks of SARS, MERS, and SARS-CoV-2 (2019).
Novavax successfully created vaccines for SARS, MERS, and are on track to create one for SARS-CoV-2 (2019) - ir.novavax.com
Vaccine in development for SARS-CoV-2 (2019): seekingalpha.com
Is this a good investment? If the vaccination is successful and/or coronavirus outbreak continues, it could trend upwards significantly.
Disclaimer: This is not financial advice. Just my own opinion based on research.
Important Notes: For your own safety, the CDC recommends you WASH YOUR HANDS FREQUENTLY. COVER YOUR MOUTHS WHEN YOU COUGH/SNEEZE.
NVAX --- Jumped $15 -promised --- NOW sold someposition for NOW NVAX --- Jumped!!! from pre-hours trading. on OPEN. ---- CAN KEEP GOING UP ---- also - Take some prfts now to be safe -- IMO.
NOW sold the position for NOW taking the very nice profits off the table....
and then wait and see next move... The technical indicators shown that it could quickly reach that high and it did ---- now since it went so soon need to wait and see....methods in DAY TRADING. IMO.
It could certainly rise more -- (BUT TAKING SURE PROFITS HERE -- IN THIS CASE IS NEVER EVER WRONG!)
It may need to close gaps from the quick rise.
Thanks
E.
___________________________________
Disclaimer:
Always do your own due diligence, full research, and homework, and consult with your own licensed investment professional before any investments. Any comments and analysis seen here are personal opinions, and we are not registered or licensed in any jurisdiction whatsoever to provide any investing advice. Any analysis, charting and comments should never be used for the purposes of assisting in any advisory decisions with any stock purchase or sale, and never to be used on the basis of making any kind of investment decisions. It is for the sole purposes of opinions and thoughts only of the markets. Thank you.
NVAX --- Great movement!! but -- caution is advised always.....NVAX --- Great movement!! Very nice chart developing here --- but be very cautious.... I believe it will climb up to the 13.90 range... (after hours it already climbed and touched in the $13.00+ dollar range before it may reverse sharply and come straight down. Alwasy be very careful with any Pharmaceutical stocks --- as they can change direction and wipe everything out in a heartbeat. Currently Novavax NVAX (along with a few others) are in processes of trying to develop vaccines for the VIRUSES...and yes currently helping with the coronavirus. (Trying to -- anyways).
Very finickly stocks...If not successful in developments in their search ---- High interest with a pump and dump type of action almost...
It can be a nice stock play if you go --- in and out --- IMO.
Not for the faint of heart. You need to know where to get in and out ---and constantly review the pattern...as it develops in front of you. Day trading at best.
Be careful.. a warning to you.
___________________________________
Disclaimer:
Always do your own due diligence, full research, and homework, and consult with your own licensed investment professional before any investments. Any comments and analysis seen here are personal opinions, and we are not registered or licensed in any jurisdiction whatsoever to provide any investing advice. Any analysis, charting and comments should never be used for the purposes of assisting in any advisory decisions with any stock purchase or sale, and never to be used on the basis of making any kind of investment decisions. It is for the sole purposes of opinions and thoughts only of the markets. Thank you.
NVAX -- Crazy climb!! In try to finding vaccine....NVAX -- Crazy climb!! In a try to reach a vaccine.... ZACKS pick The company’s expected earnings growth rate for the current year is 46% compared with the Zacks Medical - Biomedical and Genetics industry’s projected earnings growth of 8.1%. Novavax, Inc. NVAX is a late-stage biotechnology company that focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Post the virus outbreak, the company has launched a program for the coronavirus vaccine. Novavax already boasts success in vaccine development for the MERS and SARS strains.
Be careful with Pharmicuticals... can be great BUT can reverse VERY VERY quickly. Buy moderate lows. Can be shorted because of this.
SPIKING ON NEWS!! TODAY.
___________________________________
Disclaimer:
Always do your own due diligence, full research, and homework, and consult with your own licensed investment professional before any investments. Any comments and analysis seen here are personal opinions, and we are not registered or licensed in any jurisdiction whatsoever to provide any investing advice. Any analysis, charting and comments should never be used for the purposes of assisting in any advisory decisions with any stock purchase or sale, and never to be used on the basis of making any kind of investment decisions. It is for the sole purposes of opinions and thoughts only of the markets. Thank you.
$NVAX Still Seems Like a Short in the MakingNVAX is one, of all the COVID-2019 movers, that we think is most likely to end up being a great short down the line.
The long-term trajectory speaks of numerous failures to execute in clinical development, and the company is not part of the inside clique with funding to solve the virus vaccine puzzle. But it's up almost 100% since the news first broke last month.
$NVAX Coronavirus Pop May Be Rolling Over AlreadyNVAX
The "inevitability bell" may be starting to ring on this one. We called it short a few days ago -- and 7% higher. And now we may be seeing this start to play along. If short with us here, stops should be set in place in the $8.75 area to fence off the unbounded squeeze risk.
Novavax Coronavirus StockNovavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
